Company attributes
Other attributes
Established in 2021 by Barry Lutz and Minh Duong, Anavasi Diagnostics is a medical technology company specializing in the development of molecular diagnostic testing. The company develops the molecular diagnostic testing using a reverse transcriptase methodology.
Anavasi Diagnostics developed the AscencioDx™ molecular detector. The AscencioDx™ is a pre-EUA device offering COVID-19 tests for application in clinics, pharmacies, workplaces, schools, events, and other places where testing is required on the spot. The company is the recipient of a $14.9 million award from the NIH’s Rapid Acceleration of Diagnostics (RADxsm) initiative.
The AscencioDx offers the following features:
• Rapid test results
• A lower nasal swab sampling procedure
• Test results in half an hour
• A reporting process that does not require a phone app or the use of Bluetooth™
• A detector that is reusable for about 3,000 single-use COVID-19 tests
Though the intended application of the AscencioDx platform is for COVID-19 detection, a co-founder of the company, Robert Patterson, noted the technology can be applied for bacterial and viral testing.
“Its origins detecting HIV variants make it ideal for the additional detection of other viruses such as Influenza A and/or B, as well as respiratory syncytial virus, a respiratory disease that severely impacts young children, older adults, and the immunologically impaired.”
